Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Adam Cribbs has been awarded a prestigious MRC Career Development Award to further his research to identify therapeutic targets for multiple myeloma.

Adam Cribbs

Multiple myeloma (MM) is a cancer of plasma cells that has a varied response rate to treatment and a survival rate of 4-5 years. Poor survival has been attributed to drug resistance therefore identification of novel therapeutic targets for MM that overcome drug resistance is critical.

The MRC Career Development Awards, which are offered to support talented researchers to lead their own research, will enable Adam to build on his research interests in systems biology, immunology and epigenetics.

Specifically, he will develop novel, cost-effective multiplexed single-cell technologies that will provide an understanding of the relationship between the immune system and the MM tumour macroenvironment.

Commenting on his award Adam said: “I’m so pleased to have been offered the MRC award. We need to understand the cellular mechanisms that contribute to drug resistance within MM to be able to deliver better treatments. This award reinforces my belief that in time we will be able to expand the number of potential drug targets for MM, improving quality and longevity of life for patients.”

Similar stories

Patient and public involvement in Rheumatology research – embracing the wave of change

On launching the new OPEN ARMS PPI group in Oxford, Dr. Laura Coates explored the patient and public involvement (PPI) models of three academic centres in the UK to show how it benefits researchers, clinicians, and patients alike.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

NDORMS joins research partnership to understand links between overlapping long-term conditions

The links between different long-term health conditions will be explored in new research funded with a £2.5million grant from the Medical Research Council.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Researchers show the role of cilia in cartilage health

New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.

New research could improve quality of life for Psoriatic Arthritis patients

Professors Laura Coates and Dani Prieto-Alhambra will take major roles in a new European Commission project to develop innovative personalised treatment options for people affected by psoriatic arthritis.